Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 5/20 | 0.71 |
| ▸ | SRC | P12931 | 11/20 | 0.53 |
| ▸ | ABL1 | P00519 | 9/20 | 0.53 |
| ▸ | EGFR | P00533 | 9/20 | 0.53 |
| ▸ | ABL2 | P42684 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | NPM1 | P06748 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29175947 | 1.00 | RIPK2 (0.71) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL29998998 | 0.91 | RIPK2 (0.71) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL27088112 | 0.91 | RIPK2 (0.71) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL23966784 | 0.87 | RIPK2 (0.77) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL29998920 | 0.87 | RIPK2 (0.77) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL2075045 | 0.87 | RIPK2 (0.84) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL29999326 | 0.87 | RIPK2 (0.84) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL23966761 | 0.87 | RIPK2 (0.84) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL23966923 | 0.87 | RIPK2 (0.91) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL29998925 | 0.87 | RIPK2 (0.91) | RIPK2SRCABL1EGFRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | RIPK2 53/4885SRC 1649/4885ABL1 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.